|
09/07/2018 |
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory |
CIM |
Registered |
|
26/05/2014 |
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. |
CIM |
Registered |
|
15/12/2015 |
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients |
CIM |
Registered |
|
08/07/2015 |
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer |
CIM |
Registered |
|
11/10/2013 |
Randomized double blind controlled, phase I clinical trial, to assess safety, reactogenicity and immunogenicity of the 638 vaccine candidate, in healthy female and male children and adolescents aged from 5 to 17 years old from Cienfuegos Province, Cuba. |
FINLAY |
Registered |
|
2011-04-29 |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months. |
CIGB |
Registered |
|
2011-04-27 |
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 6-10-14 weeks. |
CIGB |
Registered |
|
2009-02-11 |
Recombinant IFN alpha-2b for relapsing –remitting multiple sclerosis. |
CIGB |
Registered |
|
2009-02-11 |
Recombinant interferon alpha-2b in paranoid schizophrenia. |
CIGB |
Registered |
|
05/06/2020 |
Rectal Ozone in the COVID-19 treatment |
CPN |
Registered outdated |
|
15/07/2021 |
Rectal ozone therapy in high-risk symptomatic SARS-CoV-2 positive patients |
CPN |
Registered |
|
30/05/2018 |
Results of an antimicrobial stewardship program |
CenQfal |
Registered |
|
29/10/2021 |
Retrospective observational study of the administration of Jusvinza, for the management of COVID-19 at the Hospital “Dr. Luis Diaz Soto”. |
CIGB |
Registered |
|
05/11/2013 |
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma |
CIM |
Registered outdated |
|
2009-05-29 |
rTMS-stroke-phase I |
CIREN |
Registered |
|
29/09/2017 |
Safety and effectiveness of SURFACEN® combined with the conventional therapy, in the treatment of ARDS in pediatrics. National extension |
CENSA |
Registered |
|
22/05/2021 |
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations |
CIM |
Registered outdated |
|
01/10/2020 |
Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III. |
CIM |
Registered outdated |
|
2009-02-27 |
Safety and immunogenicity of commercial Hepatitis B vaccines. |
CIGB |
Registered |
|
14/07/2020 |
Safety and immunogenicity of the CIGB 2020. |
CIGB |
Registered outdated |
